Postmarketing Surveillance Study of Atrovent® Inhalation Solution in Chronic Obstructive Pulmonary Disease
Completed
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Registration Number
- NCT02238197
- Lead Sponsor
- Boehringer Ingelheim
- Brief Summary
To obtain further information on the tolerability and efficacy of Atrovent® 500µg/2ml inhalation solution in the treatment of Chronic Obstructive Pulmonary Disease under conditions of daily practice
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 477
Inclusion Criteria
- Patients of both genders, older than 40 years,who suffer from chronic obstructive Pulmonary disease
- Only patients who had not been treated with Atrovent® within the last year were to be considered for inclusion
Exclusion Criteria
- Contraindication listed in the instructions for use/summary of product characteristics for Atrovent® 500µg/2ml Inhalation Solution
- Patients who exhibited adverse drug reactions
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Chronic Obstructive Pulmonary Disease Atrovent® Inhalation Solution -
- Primary Outcome Measures
Name Time Method Change in total severity of the clinical picture rated on a 4-point scale Up to 4 weeks after first study drug administration Investigator assessment of improvement of the clinical picture of the course on a 6-point symptoms profile up to 4 weeks after first study drug administration
- Secondary Outcome Measures
Name Time Method Assessment of efficacy by patient on a 4-point scale Up to 4 weeks after first study drug administration Assessment of tolerability by investigator on a 4-point scale Up to 4 weeks after first study drug administration Assessment of efficacy by investigator on a 4-point scale Up to 4 weeks after first study drug administration Assessment of tolerability by patient on a 4-point scale Up to 4 weeks after first study drug administration Number of patients with adverse drug reactions Up to 4 weeks after first study drug administration